National Cheng Kung University
On December 22, 2018, the 2018 BioGroup Symposium was held in the second lecture hall of College of Medicine, National Cheng Kung University in Tainan. Co-sponsored by “BioGroup Biotech Exchange Platform of Ministry of Education” and “Institute of Basic Medical Sciences of National Cheng Kung University” and co-organized by “GLORIA NCKU” and “HIT for Asia”, 2018 BioGroup Symposium focuses on the theme of "Meetup with Biotech Talents!" with the agenda covering scholastic lectures, industry forums, biotech organizations, and government programs. Through the exchanges and interactions carried out in this forum, bioscience research and biotechnology industry in Taiwan can be closely connected to inject new vitality into the future.
Under the title of “Current Status, Prospect, and Talent Cultivation of Biomedical Industry in Taiwan”, the presentation this time was delivered by Director Zhuang of Department of Life Science, Ministry of Science and Technology. Director Zhuang pointed out that the business revenue in the biomedical industry in Taiwan has being increasing over the past 5 years. According to the 2018 Global Entrepreneurship Congress on entrepreneurial ecosystems around the world, biotechnology is one of the three most advantageous industries in Taiwan. With many new startups choosing Taiwan as the developmental base, Taiwan provides an entrepreneurial environment that balances international trade and domestic demand for the new startups. Director Zhuang also expects that the biotech talents and biotechnology industries will gather their strengths and integrate their resources to focus on niche products and take part in international exhibition & business matching activities, so that the biomedical industry in Taiwan could expand its business territory to the rest of the world.
In the industry expert meeting, GLORIA NCKU invited General Manager Yang of MEDTECS INTERNATIONAL CORPORATION LIMITED, Chief Technology Officer Chen of NCKU Derivative Biotech New Startup, and Chief Operating Officer Wen of Earning (Taiwan) to exchange their industry experiences with Chief Operating Officer Hong of GLORIA NCKU and experts from other fields including Dr. Chen and Dr. Huang. General Manager Yang shared his company's market planning and distribution process before revealing his personal opinions about the educational backgrounds and relevant experiences that a biotechnological talent must obtain before devoting to the biomedical industry. Chief Executive Officer Chen and Chief Operating Officer Wen shared their entrepreneurial experiments ever since the first establishment of their companies, including life planning before and after the start of their businesses, changes in the target market of their companies, ways to expand their markets and ways to raise funds. Starting out from the first personal perspective of venture capital and entrepreneurial consultant respectively, Chief Operating Officer Hong and Dr. Huang & Dr. Chen shared their experiences on the venture capital's selection criteria of investment cases, the startups' conditions that attract venture capital to invest, and advice for biotech talents with an aspiration to start up a business in the future.
By cooperating with industry talents, GLORIA NCKU hopes to strengthen the mutual exchange and cooperation between employees working in the related industries while letting young students learn more about the pre-requisite skills and abilities they need to apply for the target industry. All these are done with an aim to achieve the talent cultivation and industry-academia cooperation.

成大國際產學聯盟營運長洪偉仁在BioGroup Symposium中分享過去創投界之經驗。

GLORIA NCKU Chief Operating Officer Hong shares his past experience with venture capital in the BioGroup Symposium.

GLORIA NCKU invites experts to share their experiences in the biotechnology industry with Office for Innovation & Entrepreneurship of National Cheng Gung University.

During his speech, Director Zhuang of Department of Life Science, Ministry of Science and Technology introduced the research and development of new drug in Taiwan.